ArticleSpine deformity2026
Neuromuscular blocking agent use in adolescent idiopathic scoliosis surgery: a safety assessment.
Article in Spine deformity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Best Practice Guidelines for the Execution of Intraoperative Neuromonitoring in Spine Deformity Surgery.Spine deformity · 2026Article
- Mivacurium Infusion ED50/ED95 for Maintaining Motor Evoked Potentials During Adolescent Scoliosis Surgery Under TIVA: A Modified Dixon Up-and-Down Sequential Dose-Finding Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNon-depolarizing neuromuscular blocking agents (nNMBAs) have been subjectively reported to make spinal exposure more efficient. However, there is concern that neuromonitoring may be compromised, even with reversal, and may mask neuromonitoring alerts or result in an increased risk of postoperative neurological complications. We sought to describe the safety of using nNMBAs to facilitate exposure in pediatric posterior spine fusion surgery (PSF).
methodsAll consecutive adolescent idiopathic scoliosis (AIS) patients who underwent PSF at a single institution between 2014 and 2022 were included. Baseline patient comorbidities, utilization of nNMBAs and reversal agents, neuromonitoring changes, surgical details, postoperative neurological deficits, and surgical complications were recorded. Patients were grouped based on nNMBA utilization (-nNMBA or +nNMBA) and their outcomes were compared using univariable and multivariable techniques. Significance was set at α = 0.05.
resultsThree hundred twenty-seven patients met all selection criteria and were included. Of these, 49 (15%) did not receive any nNMBA (-nNMBA) and 278 (85%) did receive a nNMBA (+nNMBA). Baseline patient characteristics were not different between the two groups. There were no significant differences in the rate of intraoperative neuromonitoring changes (6.1% -nNMBA versus 8.6% +nNMBA, p = 0.78), postoperative neurological deficits (6.1% -nNMBA versus 5.8% +nNMBA, p = 0.25), or postoperative complications (22.4%, -nNMBA; 21.6%, +nNMBA; p = 0.85). Modified Clavien-Dindo-Sink complication grades were not different between groups (p = 0.81).
conclusionThe study found no difference in the rate or severity of complications, rate of neuromonitoring alerts, or rate postoperative neurological changes between -nNMBA and +nNMBA groups. LEVEL OF EVIDENCE: Level III, therapeutic.
Indexed as
Identifiers
41160286What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.